Swiss Building Stock News

SWX:COTN
SWX:COTNElectronic

Assessing Comet Holding (SWX:COTN) Valuation As AI Driven Equipment Demand And Earnings Catalyst Gain Attention

Comet Holding (SWX:COTN) is back in focus after reports of stronger demand for its semiconductor and inspection equipment, particularly RF and X-ray products tied to AI uses, with a closely watched earnings date approaching. See our latest analysis for Comet Holding. Comet Holding’s recent 20.0% 1 month share price return and 49.7% 3 month share price return, with the stock now at CHF287.8, points to building momentum. At the same time, the 5 year total shareholder return of 37.4% shows more...
SWX:DKSH
SWX:DKSHTrade Distributors

A Look At DKSH Holding’s Valuation As The 2026 Earnings Release Puts Margins And Dividend Outlook In Focus

DKSH Holding (SWX:DKSH) heads into its 17 February 2026 earnings release with investors closely watching margins in Healthcare and Consumer Goods, alongside working capital metrics that could influence dividend expectations and near term sentiment. See our latest analysis for DKSH Holding. At a share price of CHF60.8, DKSH Holding has a 90 day share price return of 10.34%. Its 1 year total shareholder return of 10.59% and 3 year total shareholder return of 14.65% suggest recent momentum...
SWX:SIKA
SWX:SIKAChemicals

Sika (SWX:SIKA) Valuation Check As New Global Manufacturing Sites Come Online

Sika (SWX:SIKA) is back in focus after opening five new manufacturing sites across the United States, Argentina, Colombia, Bangladesh, and Tanzania. This broad capacity buildout tightens its supply chain for construction materials. See our latest analysis for Sika. Despite this global buildout and the relaunch of its technical training program, Sika’s CHF157.5 share price sits against a 1-year total shareholder return of a 31.7% decline and a 5-year total shareholder return of a 33.1%...
SWX:UBSG
SWX:UBSGCapital Markets

Is UBS Group (SWX:UBSG) Still Attractive After Credit Suisse Acquisition And Recent Share Pullback

If you are wondering whether UBS Group shares still offer value at current levels, you are not alone. This article is designed to help you weigh that up clearly. The stock last closed at CHF32.57, with returns of a 6.4% decline over 7 days, a 14.2% decline over 30 days and a 14.7% decline year to date, while the 1 year return sits at 12% and the 3 and 5 year returns are 74.5% and 166.5% respectively. Recent coverage has focused on UBS Group's role as a major global wealth manager and...
SWX:BAER
SWX:BAERCapital Markets

Does Julius Bär Gruppe (SWX:BAER) Still Offer Value After Recent Share Price Gains?

If you are wondering whether Julius Bär Gruppe’s current share price offers solid value or not, it helps to first step back and frame what the recent returns are actually telling you. The stock last closed at CHF63.74, with a 7 day return of a 5.3% decline, a 30 day return of a 1.9% decline, a year to date return of a 3.1% decline, but a 16.3% gain over 1 year, 20.4% over 3 years and 47.6% over 5 years. These mixed short term and longer term returns have kept interest in Julius Bär Gruppe...
SWX:ROG
SWX:ROGPharmaceuticals

Assessing Roche Holding (SWX:ROG) Valuation After Fenebrutinib Progress And Data Analytics Push

Why fenebrutinib and data analytics matter for Roche Holding stock Roche Holding (SWX:ROG) has put fresh attention on its pipeline after reporting late stage data for its oral MS candidate fenebrutinib and highlighting new data analytics platforms in clinical development. For you as a shareholder or potential investor, these updates link directly to how Roche allocates R&D spending, manages clinical risk and builds potential future revenue sources beyond its currently marketed therapies. See...
SWX:UHR
SWX:UHRLuxury

Assessing Swatch Group (SWX:UHR) Valuation After Weak Earnings And Dividend Confirmation

Earnings setback and dividend affirmation come into focus Swatch Group (SWX:UHR) is in the spotlight after full year 2025 results showed sales of CHF 6,280 million and net income of CHF 3 million, alongside confirmation of an annual dividend of CHF 4.50 per share. See our latest analysis for Swatch Group. The annual results and dividend affirmation arrived alongside strong near term momentum, with a 1 day share price return of 2.43% and a 30 day share price return of 12.53%. However, the 3...
SWX:NOVN
SWX:NOVNPharmaceuticals

Is It Too Late To Consider Novartis (SWX:NOVN) After Strong Multi‑Year Share Price Gains?

If you are wondering whether Novartis shares still offer value at around CHF 121.00, it helps to step back and look at what the current price actually implies about the company. The stock has shown solid momentum recently, with returns of 3.5% over 7 days, 6.1% over 30 days, 11.5% year to date, 27.8% over 1 year, 77.8% over 3 years and 89.7% over 5 years. Recent news flow around Novartis has focused on its position as a large pharma name and ongoing interest in its pipeline and portfolio...
SWX:SQN
SWX:SQNCapital Markets

European Growth Companies Insiders Are Eager To Own

As optimism about the eurozone economy continues to bolster investor sentiment, European markets have been experiencing a period of resilience despite recent volatility. In this environment, stocks with high insider ownership can be particularly appealing to investors, as they often suggest confidence from those closest to the company in its growth potential and strategic direction.
SWX:PGHN
SWX:PGHNCapital Markets

3 European Stocks Estimated To Be Trading At Discounts Of Up To 46%

As the pan-European STOXX Europe 600 Index reaches new intraday highs, optimism about the eurozone economy is helping to counteract recent market volatility. In this environment, identifying undervalued stocks can be particularly appealing to investors seeking opportunities that may offer potential value as the broader market sentiment remains buoyant.
SWX:PGHN
SWX:PGHNCapital Markets

European Growth Stocks Insiders Are Banking On

As optimism about the eurozone economy helps counteract recent market volatility, European markets have shown resilience with key indices like the STOXX Europe 600 Index reaching new highs. In this environment, growth companies with high insider ownership are particularly intriguing as they may signal confidence from those closest to the business, making them noteworthy in today's investment landscape.
SWX:SENS
SWX:SENSElectronic

Assessing Sensirion Holding (SWX:SENS) Valuation After Launch Of The SCD53 CO2 Sensor

Why the SCD53 CO2 sensor launch matters for Sensirion Holding (SWX:SENS) Sensirion Holding (SWX:SENS) has drawn fresh attention after announcing its SCD53 CO2 sensor, designed for long term accuracy without regular manual recalibration or outdoor air exposure in demanding applications. See our latest analysis for Sensirion Holding. That SCD53 launch lands at a time when Sensirion Holding’s 1 day share price return of 2.50% and 7 day share price return of 1.59% sit alongside a 30 day share...
SWX:LUKN
SWX:LUKNBanks

Assessing Luzerner Kantonalbank (SWX:LUKN) Valuation After Announcing Its Upcoming Annual Dividend

Luzerner Kantonalbank (SWX:LUKN) recently announced an annual dividend of CHF 1.35 per share, payable on April 20, 2026, with the ex-dividend date on April 16 and the record date on April 17. See our latest analysis for Luzerner Kantonalbank. Beyond the upcoming dividend, Luzerner Kantonalbank’s share price has been firming, with a 30 day share price return of 7.3% and a 90 day gain of 16.0%, while the 1 year total shareholder return of 49.4% points to momentum that has built over time. If...
SWX:GALD
SWX:GALDPharmaceuticals

Galderma Group (SWX:GALD) Valuation Check After FDA Accepts RelabotulinumtoxinA BLA Resubmission

Galderma Group (SWX:GALD) is back in focus after the U.S. FDA accepted its BLA resubmission for RelabotulinumtoxinA, a neuromodulator targeting adult frown lines and crow's feet in the aesthetics market. See our latest analysis for Galderma Group. The FDA update follows a mixed price pattern, with a 1-day share price return of 1.84% and a 7-day share price return of 1.63%, offset by a 30-day share price return decline of 9.56% and a year-to-date share price return decline of 6.68%. The 1-year...
SWX:COPN
SWX:COPNPharmaceuticals

Cosmo Pharmaceuticals (SWX:COPN) Valuation Check After Treasury Share Placement With Small Cap World Fund

Fresh equity placement puts Cosmo Pharmaceuticals in focus Cosmo Pharmaceuticals (SWX:COPN) has drawn attention after completing a private placement of 937,086 treasury shares, equal to 5.3% of its outstanding shares, with participation from Small Cap World Fund of the Capital Group. See our latest analysis for Cosmo Pharmaceuticals. At a share price of CHF117.0, Cosmo Pharmaceuticals has seen a 30 day share price return of 7.93% and a 90 day gain of 80.28%. Its 1 year total shareholder...